Abstract

Tumor mutational burden (TMB) is considered a potential biomarker for predicting the response and effect of immune checkpoint inhibitors (ICIs). However, there are still inconsistent standards of gene panels using next-generation sequencing and poor correlation between the TMB genes, immune cell infiltrating, and prognosis. We applied text-mining technology to construct specific TMB-associated gene panels cross various cancer types. As a case exploration, Pearson’s correlation between TMB genes and immune cell infiltrating was further analyzed in colorectal cancer. We then performed LASSO Cox regression to construct a prognosis predictive model and calculated the risk score of each sample for receiver operating characteristic (ROC) analysis. The results showed that the assessment of TMB gene panels performed well with fewer than 500 genes, highly mutated genes, and the inclusion of synonymous mutations and immune regulatory and drug-target genes. Moreover, the analysis of TMB differentially expressed genes (DEGs) suggested that JAKMIP1 was strongly correlated with the gene expression level of CD8+ T cell markers in colorectal cancer. Additionally, the prognosis predictive model based on 19 TMB DEGs reached AUCs of 0.836, 0.818, and 0.787 in 1-, 3-, and 5-year OS models, respectively (C-index: 0.810). In summary, the gene panel performed well and TMB DEGs showed great potential value in immune cell infiltration and in predicting survival.

Highlights

  • Tumor mutational burden (TMB) is considered a potential biomarker for predicting the response and effect of immune checkpoint inhibitors (ICIs)

  • We calculated TMB based on wholeexome sequencing (WES) across 32 cancer types

  • In colorectal cancer (CRC), STAD, UCEC, and skin cutaneous melanoma (SKCM), samples with TMB greater than 20 muts/MB were more than 5% (Figure S2)

Read more

Summary

Introduction

Tumor mutational burden (TMB) is considered a potential biomarker for predicting the response and effect of immune checkpoint inhibitors (ICIs). TMB can characterize tumor genome stability and tumor microenvironment (TME) heterogeneity, and serve as the prevalent biomarker to predict cancer immunotherapy response [1]. A number of studies suggest that TMB was significantly different in responders and non-responders to ICIs in melanoma [2], non-small cell lung cancer [3,4,5], and colorectal cancer (CRC) [6,7], which allows clinicians to determine who would benefit from immunotherapy. Some studies showed TMB can be estimated from a panel of only a few hundred reliable genes. One is that the optimal gene panel size varied [9]. The FDA have approved the Foundation One CDx (F1CDx) panel [10] and the FDA-authorized Memorial Sloan

Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.